Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction.

Fitzpatrick Z, Leborgne C, Barbon E, Masat E, Ronzitti G, van Wittenberghe L, Vignaud A, Collaud F, Charles S, Simon Sola M, Jouen F, Boyer O, Mingozzi F.

Mol Ther Methods Clin Dev. 2018 Feb 13;9:119-129. doi: 10.1016/j.omtm.2018.02.003. eCollection 2018 Jun 15.

2.

Rescue of GSDIII Phenotype with Gene Transfer Requires Liver- and Muscle-Targeted GDE Expression.

Vidal P, Pagliarani S, Colella P, Costa Verdera H, Jauze L, Gjorgjieva M, Puzzo F, Marmier S, Collaud F, Simon Sola M, Charles S, Lucchiari S, van Wittenberghe L, Vignaud A, Gjata B, Richard I, Laforet P, Malfatti E, Mithieux G, Rajas F, Comi GP, Ronzitti G, Mingozzi F.

Mol Ther. 2018 Mar 7;26(3):890-901. doi: 10.1016/j.ymthe.2017.12.019. Epub 2017 Dec 28.

PMID:
29396266
3.

Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

Colella P, Ronzitti G, Mingozzi F.

Mol Ther Methods Clin Dev. 2017 Dec 1;8:87-104. doi: 10.1016/j.omtm.2017.11.007. eCollection 2018 Mar 16. Review.

4.

Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors.

Meliani A, Boisgerault F, Fitzpatrick Z, Marmier S, Leborgne C, Collaud F, Simon Sola M, Charles S, Ronzitti G, Vignaud A, van Wittenberghe L, Marolleau B, Jouen F, Tan S, Boyer O, Christophe O, Brisson AR, Maguire CA, Mingozzi F.

Blood Adv. 2017 Oct 16;1(23):2019-2031. doi: 10.1182/bloodadvances.2017010181. eCollection 2017 Oct 24.

5.

Combination Therapy Is the New Gene Therapy?

Ronzitti G, Mingozzi F.

Mol Ther. 2018 Jan 3;26(1):12-14. doi: 10.1016/j.ymthe.2017.12.008. Epub 2017 Dec 20. No abstract available.

PMID:
29273499
6.

Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase.

Puzzo F, Colella P, Biferi MG, Bali D, Paulk NK, Vidal P, Collaud F, Simon-Sola M, Charles S, Hardet R, Leborgne C, Meliani A, Cohen-Tannoudji M, Astord S, Gjata B, Sellier P, van Wittenberghe L, Vignaud A, Boisgerault F, Barkats M, Laforet P, Kay MA, Koeberl DD, Ronzitti G, Mingozzi F.

Sci Transl Med. 2017 Nov 29;9(418). pii: eaam6375. doi: 10.1126/scitranslmed.aam6375.

7.

Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction.

Han SO, Ronzitti G, Arnson B, Leborgne C, Li S, Mingozzi F, Koeberl D.

Mol Ther Methods Clin Dev. 2017 Jan 11;4:126-136. doi: 10.1016/j.omtm.2016.12.010. eCollection 2017 Mar 17.

8.

Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors.

Hösel M, Huber A, Bohlen S, Lucifora J, Ronzitti G, Puzzo F, Boisgerault F, Hacker UT, Kwanten WJ, Klöting N, Blüher M, Gluschko A, Schramm M, Utermöhlen O, Bloch W, Mingozzi F, Krut O, Büning H.

Hepatology. 2017 Jul;66(1):252-265. doi: 10.1002/hep.29176. Epub 2017 May 29.

9.

Transposon-mediated Generation of Cellular and Mouse Models of Splicing Mutations to Assess the Efficacy of snRNA-based Therapeutics.

Barbon E, Ferrarese M, van Wittenberghe L, Sanatine P, Ronzitti G, Collaud F, Colella P, Pinotti M, Mingozzi F.

Mol Ther Nucleic Acids. 2016 Nov 29;5(11):e392. doi: 10.1038/mtna.2016.97.

10.

Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.

Masat E, Laforêt P, De Antonio M, Corre G, Perniconi B, Taouagh N, Mariampillai K, Amelin D, Mauhin W, Hogrel JY, Caillaud C, Ronzitti G, Puzzo F, Kuranda K, Colella P, Mallone R, Benveniste O, Mingozzi F; French Pompe Registry Study Group.

Sci Rep. 2016 Nov 4;6:36182. doi: 10.1038/srep36182.

11.

A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome.

Ronzitti G, Bortolussi G, van Dijk R, Collaud F, Charles S, Leborgne C, Vidal P, Martin S, Gjata B, Sola MS, van Wittenberghe L, Vignaud A, Veron P, Bosma PJ, Muro AF, Mingozzi F.

Mol Ther Methods Clin Dev. 2016 Jul 20;3:16049. eCollection 2016.

12.

Raft-partitioning of calcium channels regulates their function.

Ronzitti G, Bucci G, Stephens G, Chieregatti E.

Channels (Austin). 2015;9(4):169-70. doi: 10.1080/19336950.2015.1063285. No abstract available.

13.

TAAR1 Modulates Cortical Glutamate NMDA Receptor Function.

Espinoza S, Lignani G, Caffino L, Maggi S, Sukhanov I, Leo D, Mus L, Emanuele M, Ronzitti G, Harmeier A, Medrihan L, Sotnikova TD, Chieregatti E, Hoener MC, Benfenati F, Tucci V, Fumagalli F, Gainetdinov RR.

Neuropsychopharmacology. 2015 Aug;40(9):2217-27. doi: 10.1038/npp.2015.65. Epub 2015 Mar 9.

14.

Parkin regulates kainate receptors by interacting with the GluK2 subunit.

Maraschi A, Ciammola A, Folci A, Sassone F, Ronzitti G, Cappelletti G, Silani V, Sato S, Hattori N, Mazzanti M, Chieregatti E, Mulle C, Passafaro M, Sassone J.

Nat Commun. 2014 Oct 15;5:5182. doi: 10.1038/ncomms6182.

15.

GRP78 clustering at the cell surface of neurons transduces the action of exogenous alpha-synuclein.

Bellani S, Mescola A, Ronzitti G, Tsushima H, Tilve S, Canale C, Valtorta F, Chieregatti E.

Cell Death Differ. 2014 Dec;21(12):1971-83. doi: 10.1038/cdd.2014.111. Epub 2014 Aug 15.

16.

Exogenous α-synuclein decreases raft partitioning of Cav2.2 channels inducing dopamine release.

Ronzitti G, Bucci G, Emanuele M, Leo D, Sotnikova TD, Mus LV, Soubrane CH, Dallas ML, Thalhammer A, Cingolani LA, Mochida S, Gainetdinov RR, Stephens GJ, Chieregatti E.

J Neurosci. 2014 Aug 6;34(32):10603-15. doi: 10.1523/JNEUROSCI.0608-14.2014.

17.

Combined optical tweezers and laser dissector for controlled ablation of functional connections in neural networks.

Difato F, Dal Maschio M, Marconi E, Ronzitti G, Maccione A, Fellin T, Berdondini L, Chieregatti E, Benfenati F, Blau A.

J Biomed Opt. 2011 May;16(5):051306. doi: 10.1117/1.3560268.

PMID:
21639566
18.

The regulation of synaptic function by alpha-synuclein.

Bellani S, Sousa VL, Ronzitti G, Valtorta F, Meldolesi J, Chieregatti E.

Commun Integr Biol. 2010 Mar;3(2):106-9.

19.

The total activity of a mixture of okadaic acid-group compounds can be calculated by those of individual analogues in a phosphoprotein phosphatase 2A assay.

Albano C, Ronzitti G, Rossini AM, Callegari F, Rossini GP.

Toxicon. 2009 May;53(6):631-7. doi: 10.1016/j.toxicon.2009.01.026.

PMID:
19673077
20.

Proteomic analysis reveals multiple patterns of response in cells exposed to a toxin mixture.

Sala GL, Ronzitti G, Sasaki M, Fuwa H, Yasumoto T, Bigiani A, Rossini GP.

Chem Res Toxicol. 2009 Jun;22(6):1077-85. doi: 10.1021/tx900044p.

PMID:
19397276
21.

Addendum to "A cytolytic assay for the measurement of palytoxin based on a cultured monolayer cell line" [Anal. Biochem. 374 (2008) 48-55].

Bellocci M, Ronzitti G, Milandri A, Melchiorre N, Grillo C, Poletti R, Yasumoto T, Rossini GP.

Anal Biochem. 2008 Oct 1;381(1):178. No abstract available.

PMID:
18927987
22.

Protein markers of algal toxin contamination in shellfish.

Ronzitti G, Milandri A, Scortichini G, Poletti R, Rossini GP.

Toxicon. 2008 Nov;52(6):705-13. doi: 10.1016/j.toxicon.2008.08.007. Epub 2008 Aug 20.

PMID:
18782583
23.

Yessotoxin induces the accumulation of altered E-cadherin dimers that are not part of adhesive structures in intact cells.

Ronzitti G, Rossini GP.

Toxicology. 2008 Feb 28;244(2-3):145-56. Epub 2007 Nov 21.

PMID:
18155345
24.

A cytolytic assay for the measurement of palytoxin based on a cultured monolayer cell line.

Bellocci M, Ronzitti G, Milandri A, Melchiorre N, Grillo C, Poletti R, Yasumoto T, Rossini GP.

Anal Biochem. 2008 Mar 1;374(1):48-55. Epub 2007 Nov 20.

PMID:
18023406
25.

Azaspiracid-1 alters the E-cadherin pool in epithelial cells.

Ronzitti G, Hess P, Rehmann N, Rossini GP.

Toxicol Sci. 2007 Feb;95(2):427-35. Epub 2006 Nov 21.

PMID:
17118960
26.

Selective disruption of the E-cadherin-catenin system by an algal toxin.

Ronzitti G, Callegari F, Malaguti C, Rossini GP.

Br J Cancer. 2004 Mar 8;90(5):1100-7.

Supplemental Content

Loading ...
Support Center